# Olanzapine for Cancer Related Anorexia-cachexia Syndrome

> **NCT06517199** · PHASE3 · RECRUITING · sponsor: **Mahidol University** · enrollment: 138 (estimated)

## Conditions studied

- Anorexia
- Cachexia

## Interventions

- **DRUG:** Olanzapine 2.5 MG
- **DRUG:** Olanzapine 5 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06517199
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-22
- **Primary completion:** 2026-01-21
- **Final completion:** 2026-01-21
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2024-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06517199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06517199, "Olanzapine for Cancer Related Anorexia-cachexia Syndrome". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06517199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*